Dr. Anagnostou is an Associate Professor of Oncology, Director of the Thoracic Oncology Biorepository and co-leader of the Molecular Tumor Board in the Sidney Kimmel Cancer Center at Johns Hopkins. She graduated from Medical School of the National and Kapodistrian University of Athens, Greece and received a PhD from the same institution. Dr. Anagnostou completed her internal medicine residency at Yale-New Haven Hospital and subsequently trained in Medical Oncology at Johns Hopkins. She is a
translational cancer investigator who is focusing on large-scale genomic, multi-omic and liquid biopsy analyses in human cancers, especially in lung cancer and mesothelioma. Her research is particularly focused on understanding the molecular mechanisms of response and resistance to immunotherapy and translating this knowledge into novel
technologies and innovative therapeutic approaches for cancer patients treated with immunotherapy. Her long term goal is to transform medical oncology to molecular oncology, where treatment decisions are tailored not only to a baseline genotype but are also informed by real-time dynamics of liquid biopsies.

Dr. Rotow is a thoracic medical oncologist at the Dana-Farber Cancer Insitute. She received her M.D. from the UCLA David Geffen School of Medicine. She completed her residency training in Internal Medicine at the Massachusetts General Hospital and her fellowship training in Hematology/Oncology at the University of California, San Francisco. Her research interests include the development of targeted therapies and immunotherapies for the treatment of oncogene-driven lung cancer.